Molybdenum for Health & Longevity - Quick Reference Sheet

Molybdenum for Health & Longevity

Created on 09/27/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / GPT 6 – Audit

Molybdenum is an essential dietary mineral used in supplements to support normal body processes. Maintaining adequate intake is supported; extra supplementation remains unproven for longevity. Enriched lettuce offers a short-term blood-sugar signal, but no established effective longevity dose or durable benefit. Long-term safety remains uncertain; kidney function, copper status, and total intake matter. (Full Review)

Protocol

Nutritional amounts
45 micrograms/day total
US adult allowance; 50 micrograms/day in pregnancy and lactation. Nutritional amounts, not supplemental longevity doses.
Time and divided doses
No superior timing established
Products commonly use one daily serving; splitting has no demonstrated clinical advantage.
Deficiency treatment
Individually prescribed replacement
During intravenous nutrition; no general oral rescue dose established from the historical case.
Time to effect
Lower fasting glucose with enriched lettuce
12 days
Measured laboratory change; no established time to noticeable benefit.
Stronger bones
12-day marker study
Enriched lettuce changed markers; tablets did not. No fracture or bone-density benefit demonstrated.

Benefits

Contraindications
  • Documented allergy to the specific formulation (that product).
  • Established copper deficiency (discretionary supplementation).
  • Advanced kidney impairment or dialysis (unsupervised additional intake).
  • Pregnancy, breastfeeding, or pursuing fertility (experimental high-dose longevity regimens).
Key Interactions
  • Copper and zinc (high-dose zinc)
  • Glucose-lowering drugs (theoretical; insulin, sulfonylureas: glipizide, gliclazide)
  • Acetaminophen/paracetamol (theoretical concern)
  • Other prescription and nonprescription drugs (multiple medications plus kidney or liver disease)
  • Other supplements (multivitamins, trace-mineral blends, standalone products)
  • Copper-binding treatment (penicillamine, trientine, tetrathiomolybdate)

Risk & Side Effects

  • High:
  • Medium: Heart failure association; higher diabetes prevalence.
  • Low: Neurological and psychiatric toxicity; gout-like illness at excessive exposure; impaired reproductive function; lower bone density in older women; preterm birth association; cleft lip or palate associations; asthma association in metal mixtures; cancer-mortality signals with combined supplementation; all-cause mortality association; widening pulse pressure; lower infant motor-development scores; childhood emotional and behavioral difficulties; frailty association in older adults; fatty-liver association; abdominal pain and leg swelling.
  • Speculative: Copper depletion from ordinary supplements; nonspecific intolerance and allergy.

Monitoring

Marker Target Why
Plasma/serum or urinary molybdenum No established optimization target; baseline and laboratory interval Document exposure
Serum creatinine and estimated glomerular filtration rate No molybdenum-specific target; baseline and clinically appropriate kidney range Assess clearance
Serum copper and ceruloplasmin No molybdenum-specific optimal range; laboratory interval and baseline Detect imbalance
Complete blood count No molybdenum-specific target; baseline hemoglobin and white-cell counts Assess suspected copper effects
Serum uric acid No molybdenum optimization target; baseline and existing gout-treatment target Assess gout context
Fasting glucose No molybdenum-specific optimal range; baseline and established diabetes goals Test metabolic claims

Cadence: No trial validates a monitoring cadence. Proposed: 2–4 weeks, then every 3–6 months during experimental use; earlier for symptoms. Routine screening is not established for adequately nourished adults.

Qualitative Assessment

  • Qualitative outcomes: Energy, intestinal symptoms, sleep, function, and concurrent changes.
  • Adverse outcomes: Joint pain, swelling, abdominal pain, neurological symptoms, and reproductive concerns.